Home Tags Metastatic castration-resistant prostate cancer

Tag: metastatic castration-resistant prostate cancer

Fusion Pharmaceuticals Confirms Clinical Program and Shares Manufacturing Updates

Clinical-stage oncology Fusion Pharmaceuticals, which focuses on the developing of the next-generation radiopharmaceuticals as precision medicines, confirmed significant progress in the development of FPI-2265...

FDA Grants Fast Track Designation for ARX517 in Metastatic Castration-Resistant Prostate...

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ARX517, a proprietary anti-PSMA antibody-drug conjugate (ADC) investigational being therapy developed by Ambrx for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) upon progression on an androgen receptor pathway inhibitor.